Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study. Blood 2025;145(3):300-10. Abstract
Badros A et al. Diagnosed multiple myeloma after transplant: Primary results from the phase 3 AURIGA study. IMW 2024;Abstract OA-45.
Beksac M et al. Belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: A subset analysis in patients who have received 1 prior line of therapy including lenalidomide. ASH 2024;Abstract 4731.
Dhakal B et al. Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database. ASCO 2023;Abstract e19508.
Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med 2025;392(18):1777-88. Abstract
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract
Dimopoulos MA et al. Daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D-VRD) with D-R maintenance (MAINT) in transplant-eligible (TE) newly diagnosed myeloma (NDMM): Analysis of PERSEUS based on cytogenetic risk. EHA 2024;Abstract P974.
Dimopoulos MA et al. Phase 3 randomized study of daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Primary results of the Aquila study. ASH 2024;Abstract 773.
Einsele H et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVD OR DPD) in lenalidomide-refractory multiple myeloma. EHA 2023;Abstract S100.
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(17):1597-609. Abstract
Facon T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104-15. Abstract
Foster L et al. Daratumumab plus lenalidomide (D-R) versus lenalidomide (R) alone as maintenance therapy in newly diagnosed multiple myeloma (NDMM) after transplant: Analysis of the phase 3 Auriga study among clinically relevant subgroups. ASH 2024;Abstract 675.
Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.
Goldschmidt H et al. Isatuximab, lenalidomide, bortezomib and dexamethasone induction therapy for transplant-eligible patients with newly diagnosed multiple myeloma: Final progression-free survival analysis of part 1 of an open-label, multicenter, randomized, phase 3 trial (GMMG-HD7). ASH 2024;Abstract 769.
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.
Kowalski A et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH 2024;Abstract 932.
Mateos M-V et al. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 439572.
Orlowski RZ et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM): Analyses of minimal residual disease (MRD) negativity dynamics in the phase 3 Imroz study. ASH 2024;Abstract 770.
Popat R et al. Ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SoC) in patients with lenalidomide (Len)-refractory multiple myeloma (MM) after 1–3 lines of therapy: Minimal residual disease (MRD) negativity in the phase 3 Cartitude-4 trial. ASH 2024;Abstract 1032.
Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract
Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390(4):301-13. Abstract
Sonneveld P et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (Pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): Primary results of the Perseus trial. ASH 2023;Abstract LBA-1.
Terpos E et al. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study. Haematologica 2024;109(8):2594-605. Abstract
Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.
Usmani SZ et al. Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis. ASH 2024;Abstract 497.
Zamagni E et al. Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus Len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): Safety run-in (SRI) results from the Majestec-4/EMN30 trial. ASH 2024;Abstract 494.
Zweegman S et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: Analysis of minimal residual disease in the Cepheus trial. ASH 2024;Abstract 362.